23:21:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2023-05-30 Ordinarie utdelning LIDDS 0.00 SEK
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-29 Årsstämma 2023
2023-03-13 Bokslutskommuniké 2022
2023-01-09 Extra Bolagsstämma 2022
2022-11-28 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-06-02 Ordinarie utdelning LIDDS 0.00 SEK
2022-06-01 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-22 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning LIDDS 0.00 SEK
2021-05-18 Kvartalsrapport 2021-Q1
2021-05-17 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning LIDDS 0.00 SEK
2020-05-14 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-28 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-17 Ordinarie utdelning LIDDS 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018
2018-11-29 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning LIDDS 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-05-16 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-10-06 Extra Bolagsstämma 2017
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-12 Ordinarie utdelning LIDDS 0.00 SEK
2017-05-11 Årsstämma 2017
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-06-09 Extra Bolagsstämma 2016
2016-04-22 Årsstämma 2016
2016-04-22 Kvartalsrapport 2016-Q1
2016-04-21 Ordinarie utdelning LIDDS 0.00 SEK
2016-02-10 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-04-22 Ordinarie utdelning LIDDS 0.00 SEK
2015-04-21 Kvartalsrapport 2015-Q1
2015-04-21 Årsstämma 2015
2015-02-20 Bokslutskommuniké 2014
2014-11-11 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2


ListaFirst North Stockholm
LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System och bolaget har sitt huvudkontor i Uppsala.
2022-06-01 15:30:00

The annual general meeting in LIDDS AB (PUBL) (“LIDDS” or the “Company”) was held on 1 June 2022 and in particular the following decisions were resolved.

  • The annual general meeting adopted the income statement and balance sheet and the consolidated income statement and consolidated balance sheet for the financial year 2021.
  • The annual general meeting resolved that no dividend shall be paid for the financial year 2021 and decided to carry forward the earnings. Furthermore, the annual general meeting granted discharge from liability for the bord of directors and CEO for the financial year 2021.
  • The Annual general meeting resolved to re-elect board members Jan Törnell, Maria Forss, Daniel Lifveredson and David Bejker. Further, Max Mitteregger and Johan Lund ware elected as new board members. Jan Törnell was re-elected as chairman of the board. The registered accounting firm Öhrlings PricewaterhouseCoopers AB was re-elected as auditor. Öhrlings PricewaterhouseCoopers AB has appointed Tobias Albing as auditor in charge.
  • The annual general meeting resolved to approve a fee to the directors of the board of a total of SEK 787,500, of which SEK 225,000 is to be paid to the chairman of the board and SEK 112,500 to each of the other ordinary members of the board. Remuneration for work in the audit committee was resolved by the AGM to SEK 50,000 to the chairman of the audit committee and SEK 25,000 to each of the other audit committee members. The auditor’s fees shall be paid in accordance with approved invoice.
  • The annual general meeting resolved that the nomination committee prior to the annual general meeting 2023 shall consist of four members, of which three of those shall be appointed by the two largest shareholders as of end of September. The fourth member shall be chairman of the bord of directors. The nomination committee shall draft proposal of board members, proposal of chair of the bord of directors, proposal of remuneration for bord of directors, proposal of auditor, proposal of remuneration for auditor and proposal of guidelines for appointment of nomination committee.
  • The annual general meeting resolved to authorise the Board of directors to, within the scope of the articles of association, with deviation from the shareholders’ pre-emption rights, on one or several occasions during the period until the next annual general meeting, resolve to issue convertibles in the Company in accordance with the financing agreement that the Company entered into with Nice & Green S.A. on 22 February 2022. The number of shares that may be issued upon conversion of so issued convertibles shall be a maximum of 25,760,209 shares.
  • The annual general meeting resolved on a share issue with deviation from the shareholders preferential rights of a maximum of 750,000 shares, entailing an increase in the Company's share capital by SEK 39,750. The right to subscribe for new shares in the share issue shall be vested in Galba Holding AB. The shares shall be subscribed for at a price of SEK 6 per share, which provides issuing proceeds of up to approximately SEK 4,500,000. The reasons for the deviation from the shareholders' preferential rights are to provide the Company with strategically important shareholders. Galba Holding AB is owned by Max Mitteregger, a reputable investor who has also offered to take a seat in the Company's board, which is considered to be positive for the Company's future development.
  • The annual general meeting resolved to authorise the bord of directors to, on one or more occasions during the period until the next annual general meeting, with or without deviation from the shareholders preferential rights, decide on issue of shares. Share issues may be made with or without provision on non-cash contributions, set-off or other conditions. The maximum number of shares to be issued corresponds to thirty per cent of the total number of shares in the company at the time of the annual general meeting and the issue price shall be in accordance with market conditions.
  • The annual general meeting resolved to change the limits in the articles of association with respect to share capital and number of shares (§§ 4 and 5). § 4 is changed to “The share capital amounts to a minimum of SEK 1,700,000 and a maximum of SEK 6,800,000.”. § 5 is changed to “The number of shares shall be a minimum of 30,000,000 and a maximum of 120,000,000.”.

Notice and complete proposals are available on the company's website: https://liddspharma.com/investors/#corporate-governance